ACTO

SEPTEMBER 11, 2024

The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. Current solutions are almost exclusively focused on marketing, HCP targeting, workflow automation, and performance insight.

Science 52

Science Pharma Companies Production Marketing 52

Agency IQ

JUNE 7, 2024

FDA’s new guidance explains what to do during a BIMO inspection Under the FDA’s Bioresearch Monitoring (BIMO) program, the agency oversees the operation of regulated research. In short, the BIMO program oversees regulated research – both human and animal – in a variety of ways.

FDA 40

FDA Compliance Regulations Production 40

Drug Discovery World

AUGUST 8, 2023

DDW’s Megan Thomas takes a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest. Investment According to Invest India, the Indian pharmaceutical industry is expected to reach $65 billion by 2024 and to $130 billion by 20305.

Research 130

Research Pharmacy Pharmaceuticals Government 130

Drug Discovery World

SEPTEMBER 26, 2024

He explained how the history of SRC research has always been inherently linked with cancer research. The compound has now been licensed to Nuvectis Pharma who started Phase I trials in 2024 in various cancers. She comments: “We are grateful for the opportunity to present CDD Vault at the Drug Discovery Scottish Forum.

Small Molecule 147

Small Molecule Drugs Therapies Disease 147

Drug Discovery World

JULY 3, 2024

DDW’s Diana Spencer takes a closer look into why Switzerland is such a life sciences powerhouse and how Swiss researchers are advancing new technology and tackling modern health challenges. Swiss companies are also applying AI beyond preclinical drug discovery, to clinical trials and upskilling staff.

Drugs 130

Drugs Clinical Trials Science Therapies 130

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Additionally, the smaller potential customer base may provide an insufficient return on the investment into research.

Marketing 40

Marketing Biosimilars Regulations Drugs 40

Codon

JUNE 2, 2024

It took another five years for a pair of American researchers to come up with an explanation before going on to pioneer the mouse as biomedicine’s premier model organism. It took another century after Mendel’s pea experiments for the mouse to become an established presence in research labs.

Laboratories 117

Laboratories Research Disease Science 117